FindTrial
Sign In

AZD2936

DRUG4 trials

Sponsors

AstraZeneca, University Health Network, Toronto

Conditions

Advanced or Metastatic NSCLCLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)Metastatic Non-Small Cell Lung Cancer (NSCLC)Non-Small-Cell Lung Carcinoma

Phase 1

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Active, not recruitingNCT03819465
AstraZenecaMetastatic Non-Small Cell Lung Cancer (NSCLC)
Start: 2018-12-27End: 2026-03-26Updated: 2026-02-11
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Active, not recruitingNCT04612751
AstraZenecaAdvanced or Metastatic NSCLC
Start: 2021-02-02End: 2026-04-30Updated: 2025-12-18
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Active, not recruitingNCT04995523
AstraZenecaNon-Small-Cell Lung Carcinoma
Start: 2021-09-14End: 2028-06-01Updated: 2026-03-24

Phase 2

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
RecruitingNCT05414032
University Health Network, TorontoLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Start: 2023-07-12End: 2028-07-01Target: 102Updated: 2026-02-25

Related Papers

Abstract 5546: Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC
Cancer Research2026-04-03
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.
2025-11-07
First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).
Journal of Clinical Oncology2025-05-285 citations
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer
Future Oncology2024-10-2911 citations
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
Journal of Clinical Oncology2023-06-0117 citations
TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).
Journal of Clinical Oncology2023-06-0110 citations
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Cancer Immunology Immunotherapy2023-04-0589 citations
469 Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT
Regular and Young Investigator Award Abstracts2022-11-016 citations